Silibinin has been found to reduce lipid inflammatory responses by regulating inflammatory mediators such as TGF-β and IL-4/IL-10, ameliorating lipid metabolism-related diseases (Surai et al., 2024). The gene discussed is IL10; the disease is glycogen storage disease VI.